Turnstone Biologics Corp. Common Stock (TSBX) - Total Assets
Based on the latest financial reports, Turnstone Biologics Corp. Common Stock (TSBX) holds total assets worth $21.11 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Turnstone Biologics Corp. Common Stock for net asset value and shareholders' equity analysis.
Turnstone Biologics Corp. Common Stock - Total Assets Trend (2021–2024)
This chart illustrates how Turnstone Biologics Corp. Common Stock's total assets have evolved over time, based on quarterly financial data.
Turnstone Biologics Corp. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Turnstone Biologics Corp. Common Stock's total assets of $21.11 Million consist of 85.3% current assets and 14.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 72.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Turnstone Biologics Corp. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Turnstone Biologics Corp. Common Stock (TSBX) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Turnstone Biologics Corp. Common Stock's current assets represent 85.3% of total assets in 2024, a decrease from 94.7% in 2021.
- Cash Position: Cash and equivalents constituted 72.1% of total assets in 2024, up from 65.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Turnstone Biologics Corp. Common Stock Competitors by Total Assets
Key competitors of Turnstone Biologics Corp. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Turnstone Biologics Corp. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.33 | 4.38 | 2.81 |
| Quick Ratio | 3.33 | 4.38 | 2.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $14.76 Million | $52.77 Million | $63.17 Million |
Turnstone Biologics Corp. Common Stock - Advanced Valuation Insights
This section examines the relationship between Turnstone Biologics Corp. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.56 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | -64.4% |
| Total Assets | $40.14 Million |
| Market Capitalization | $8.21 Million USD |
Valuation Analysis
Below Book Valuation: The market values Turnstone Biologics Corp. Common Stock's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Turnstone Biologics Corp. Common Stock's assets decreased by 64.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Turnstone Biologics Corp. Common Stock (2021–2024)
The table below shows the annual total assets of Turnstone Biologics Corp. Common Stock from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $40.14 Million | -64.42% |
| 2023-12-31 | $112.81 Million | -1.85% |
| 2022-12-31 | $114.94 Million | -38.62% |
| 2021-12-31 | $187.24 Million | -- |
About Turnstone Biologics Corp. Common Stock
Turnstone Biologics Corp. operates as a biotechnology company. The company was founded in 2014 and is headquartered in San Diego, California. As of August 11, 2025, Turnstone Biologics Corp. operates as a subsidiary of XOMA Royalty Corporation.